|Bid||254.00 x N/A|
|Ask||267.00 x N/A|
|Day's range||256.80 - 260.75|
|52-week range||256.00 - 404.10|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||15.96|
|Forward dividend & yield||9.50 (3.38%)|
|Ex-dividend date||16 Mar 2023|
|1y target est||N/A|
Berkshire Hathaway, Roche Holding, Thermo Fisher Scientific, Mitsubishi UFJ Financial Group and Synopsys are included in this Analyst Blog.
Swiss pharmaceutical company Roche (OTC: RHHBY) took a hit from a decline in sales of COVID-19 diagnostic and treatment products in 2022, with group sales inching up 2% at constant exchange rates (CER) to 63.28 billion Swiss francs ($68.34 billion). The company's pharmaceutical and diagnostic divisions were both affected, and net income came in at 13.5 billion francs ($14.6 billion), a decline of 6% compared to 2021 under international financial reporting standards (IFRS). The company expects "the sharp decline in sales of COVID-19 products" to continue through 2023, leading sales to decrease "in the low single digit range," although it also expects its sales of other products to show strong growth.
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Roche Holding AG (RHHBY) and Thermo Fisher Scientific Inc. (TMO).